Arlene Siefker-Radtke

Arlene Siefker-Radtke is a bladder and urothelial cancer specialist who has contributed to characterizing molecular subtypes of urothelial carcinoma and translating these into therapeutically actionable categories. She has been an investigator on multiple clinical trials of FGFR inhibitors, immunotherapy, and antibody-drug conjugates in bladder cancer. She has particular expertise in rare bladder cancer histologies including small cell and variant histologies. Her translational research connects molecular profiling with clinical outcomes and treatment selection for patients with advanced urothelial carcinoma.